Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 5/20 | 0.33 |
| ▸ | JAK1 | P23458 | 5/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16709104 | 0.85 | NR1H2 (0.35) | JAK2JAK1GPR119 | |
| SCHEMBL16709109 | 0.85 | MEN1 (0.35) | MEN1KMT2AJAK2JAK1MMP13 | |
| SCHEMBL16730741 | 0.75 | CSNK1E (0.39) | — | |
| SCHEMBL16700544 | 0.74 | KMT2A (0.31) | KMT2A | |
| SCHEMBL29045144 | 0.72 | KMT2A (0.45) | MEN1KMT2AMMP13P2RX7STS | |
| SCHEMBL16709102 | 0.72 | NR1H2 (0.34) | JAK2JAK1GPR119 | |
| SCHEMBL16709112 | 0.72 | CSNK1E (0.40) | — | |
| SCHEMBL26855934 | 0.71 | KMT2A (0.47) | MEN1KMT2AMMP13P2RX7STS | |
| SCHEMBL25284834 | 0.70 | KMT2A (0.47) | MEN1KMT2AMMP13P2RX7STS | |
| SCHEMBL18991406 | 0.69 | KMT2A (0.46) | MEN1KMT2AMMP13P2RX7STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | MEN1 4028/4885KMT2A 1919/4885JAK2 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.